Table 2. Surface marker deregulated on resting or activated CD4⁺ T cells from Alagille Syndrome patients.

	Jagged1		Notch1		CD46		CD127		CD132
	NA	CD3 CD46	NA	CD3 CD46	NA	CD3 CD46	NA	CD3 CD46	NA	CD3C D46
HD1	+	↑	+	↑	+	↓	+	↓	+	↑
HD2	+	↑	+	↑	+	↓	+	↓	+	↑
AP1	+ (↑)	↑(↑)	+	↑	+	↓	+	↑	+ (↑↑)	↑↑
AP2	+ (↑)	↑(↑)	+	↑	+	↓ (50%)	+	↓	+ (↑)	↔
AP3	+ (↑)	↑(↑)	+ (↓)	↑	+	↔	+	↓	+ (↑)	↔
AP4	+ (↑)	↔	+ (↓)	↑	+	↓	+(↑↑)	↔	+ (↑↑)	↔ a

+, present on resting T cells; ↑, increased expression upon activation; ↓, decreased expression upon activation; (↑); increased baseline expression compared to HD1 and 2 (≤ 250%); (↑↑), increased baseline expression compared to HD1 and 2 (< 250%); (↓), decreased baseline expression compared to HD1 and 2; ↔, no change in expression compared to non-activated sample;

^aexpression remains increased compared to HDs (Supplementary Fig. 6)

AP, Alagille Syndrome patient; HD, healthy donor; NA, non-activated